LuLym-T (autologous activated lymphocytes) / Lujia Biomedical - LARVOL DELTA

Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=95 | Recruiting | Sponsor: Lukas Biomedical Inc. | Trial completion date: Jun 2027 ➔ Oct 2028 | Trial primary completion date: Dec 2026 ➔ Dec 2027

Trial completion date • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=95 | Recruiting | Sponsor: Lukas Biomedical Inc. | Trial primary completion date: Jun 2026 ➔ Dec 2026 | Trial completion date: Aug 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor

GC Cell and Taiwan Lucas collaborate on developing immune cell therapy [Google translation] (HIT News) - "GC Cell...announced on the 22nd that it has signed a strategic collaboration agreement with Taiwan's Lukas Biomedical (Chairman Eric Tang) for the development of immune cell therapy and market expansion....Through this collaboration agreement with Lucas Biomedical, GC Cell plans to conduct joint research on the mechanism of action and clinical data of autologous immune cell therapy and strengthen the global awareness of T cell therapy. Through this, it is expected to promote the clinical efficacy and safety of autologous immune cell therapy as well as enter the global market and further expand ImmuneCell LC....Under this agreement, GC Cell will provide domestic clinical trial data (Real World Data, RWD) of ImmuneCell LC, and Lucas Biomedical will share research and clinical data of LuLym-T secured in Taiwan, and cooperate in additional process development and expansion of clinical indications in the future."

Licensing / partnership • Gastrointestinal Cancer • Liver Cancer • Oncology • Solid Tumor

Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=95 | Recruiting | Sponsor: Lukas Biomedical Inc. | Trial completion date: Dec 2023 ➔ Aug 2026 | Trial primary completion date: Dec 2023 ➔ Jun 2026

Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Efficacy and Safety of Activated T Lymphocytes (ATL) in Hepatocellular Carcinoma (clinicaltrials.gov) - P2 | N=95 | Recruiting | Sponsor: Lukas Biomedical Inc.

New P2 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • AFP